Diversification of Big Pharma into generics and biosimilars Posted 05/08/2011

The infamous patent cliff is upon us and most top multinational companies are highly exposed with thin pipelines [1]. In this current climate, companies can choose to play or defend to optimise their position against generics.
Challenges Challenges facing the pharmaceutical industry in the coming years are many and include: In order to survive the pharmaceutical industry has in many cases gone along with the old adage ‘if you can’t beat them join them’ and gone over to the old enemy camp of the generics industry. The patent cliff Approximately US$186 billion in sales revenues of patent-protected medicines is likely to be exposed to generic competition between 2010 and 2016. On average, 44% of top 20 company sales are at risk to generic competition between 2009 and 2014. Companies basically have two options, either to diversify into generics or to defend through effective lifecycle and portfolio management. Diversify into generics This diversification could help to compensate for brand erosion following patent expiration: Generic diversification strategies Multinational research and development-based companies are diversifying into generics and employing several different strategies, including some of the following: Related articles Not only generics makers are well placed to move into biosimilars Big Pharma and the generics industry The growth in the generics industry Patent cliff and the generics industry Reference 1. Sheppard A. Generics; opportunities for some, threats for others: strategy shifts and new business models as a consequence. 5th Annual Generics Asia Summit 2010; 2010 Oct 25–26; Singapore.
Comments (0)
Generics News Research General
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
- Biocon and Lupin launch generic tacrolimus caps...Generics/News | Posted 05/02/2021
- New generics company to offer low-cost versions...Generics/General | Posted 29/01/2021
Biosimilars News Research General
- Improving stakeholder understanding about biosi...Biosimilars/Research | Posted 19/02/2021
- Canada approves infliximab biosimilar Remsima SCBiosimilars/News | Posted 19/02/2021
- Innovent starts phase II trial for ipilimumab c...Biosimilars/News | Posted 19/02/2021
- EMA recommends approval of adalimumab biosimila...Biosimilars/News | Posted 12/02/2021